Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0UIZFH
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
XB3-001
|
|||||
| Synonyms |
Melanotransferrin-trastuzumab conjugate (biOasis); MTf-TZM; MTfp-TZM; p97-trastuzumab conjugate (T)
Click to Show/Hide
|
|||||
| Organization |
Bioasis Technologies, Inc.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 2 Indication(s)
Brain cancer [ICD11:2A00]
Clinical candidate
Glioblastoma [ICD11:2A00]
Clinical candidate
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.